Clear Filters
6 results
  • CFFC-OB-11

    A Long-Term Prospective Observational Safety Study of the Incidence of and Risk Factors for Fibrosing Colonopathy in US Patients with Cystic Fibrosis Treated with Pancreatic Enzyme Replacement Therapy: A Harmonized Protocol Across Sponsors

    For inquiries, call (732) 222-4474
    • Robert Wood Johnson University Hospital
  • OPTIMIZE-IP-12

    OPTIMIZing Treatment for Early Pseudomonas aeruginosa Infection in Cystic Fibrosis The OPTIMIZE Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial. (IRB Registration #00003104)

    For inquiries, call (732) 222-4474
    • Robert Wood Johnson University Hospital
  • Participation in the Cystic Fibrosis Patient Registry

    (IRB Registration # 00003104)

    For inquiries, call (732) 222-4474
    • Robert Wood Johnson University Hospital
  • PTC124-GD-021-CF

    A Phase 3 Efficacy And Safety Study Of Ataluren (PTC124®) In Patients With Nonsense Mutation Cystic Fibrosis. (IRB Registration #00003104)

    For inquiries, call (732) 222-4474
    • Robert Wood Johnson University Hospital
  • The EPIC Observational Study

    Longitudinal Assessment of Risk Factors for and Impact of Pseudomonas Aeruginosa Acquisition and Early Anti-Pseudomonal Treatment in Children with CF (IRB Registration # 00003104)

    For inquiries, call (732) 222-4474
    • Robert Wood Johnson University Hospital
  • VX14-661-106

    A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CF

    For inquiries, call (732) 222-4474
    • Robert Wood Johnson University Hospital